Nisa Investment Advisors LLC Purchases 750 Shares of AstraZeneca PLC (NASDAQ:AZN)

Nisa Investment Advisors LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 115.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,400 shares of the company’s stock after acquiring an additional 750 shares during the quarter. Nisa Investment Advisors LLC’s holdings in AstraZeneca were worth $103,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of AstraZeneca by 189.3% during the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company’s stock worth $1,574,247,000 after acquiring an additional 15,722,197 shares during the period. Marshall Wace LLP acquired a new stake in AstraZeneca during the 4th quarter valued at $254,018,000. Alyeska Investment Group L.P. boosted its position in AstraZeneca by 220.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 3,027,511 shares of the company’s stock worth $198,363,000 after purchasing an additional 2,083,645 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of AstraZeneca by 815.8% in the fourth quarter. Point72 Asset Management L.P. now owns 1,073,630 shares of the company’s stock valued at $70,344,000 after purchasing an additional 1,223,630 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of AstraZeneca by 65.1% in the fourth quarter. Alliancebernstein L.P. now owns 3,101,025 shares of the company’s stock valued at $203,179,000 after purchasing an additional 1,222,669 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.7%

AZN stock opened at $68.79 on Friday. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The stock has a market capitalization of $213.34 billion, a price-to-earnings ratio of 27.63, a PEG ratio of 1.27 and a beta of 0.37. The business’s fifty day moving average price is $70.78 and its two-hundred day moving average price is $70.92.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same period last year, the firm earned $2.06 earnings per share. AstraZeneca’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on AZN. BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 target price for the company. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a research report on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.